Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

It’s a big week for FDA advisory committee meetings. Allison, Elaine, and Adam discuss Capricor Therapeutics’ hearing in front of an FDA advisory committee. The company is asking the agency to approve its treatment for Duchenne, but advisers have questioned the data the company presented. They also discuss Replimmune’s meeting with advisers to discuss its immunotherapy for melanoma.

The hosts further discuss the latest news in the life sciences, including new details on how a fugitive worked as a biotech executive, cuts at GSK, and Sarepta Therapeutics’ new CEO.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.